Assess whether to re-trade, restructure, or drop after a founder who will not

SITUATION The working file is regulatory-approval critical-path calendar after a founder who will not sign a non-compete. Buy-side QoE lead in a roll-up of three regional service companies has to name To re-trade, restructure, or Drop for this M&A Due Diligence People and Contracts file.

DECISION Buy-side QoE lead in a roll-up of three regional service companies must choose To re-trade, restructure, / Drop using regulatory-approval critical-path calendar after a founder who will not sign a non-compete.

HYPOTHESES TO TEST 1. Buy-side QoE lead can defend To re-trade, restructure, from regulatory-approval critical-path calendar after a founder who will not sign a non-compete in a M&A Due Diligence challenge. 2. Buy-side QoE lead cannot defend To re-trade, restructure, from regulatory-approval critical-path calendar; Drop is what the extract actually supports after a founder who will not sign a non-compete. 3. A founder who will not sign a non-compete never reached the population in regulatory-approval critical-path calendar — reopen intake, do not close to re-trade, restructure, or drop. 4. Two facts in regulatory-approval critical-path calendar after a founder who will not sign a non-compete conflict for buy-side QoE lead; hold this People and Contracts file.

ANALYSIS REQUIRED 1. Map reps, earnout mechanics, and integration risk a roll-up of three regional service companies would inherit. 2. Tie quality-of-earnings, working-capital, and contingent items in regulatory-approval critical-path calendar to to re-trade, restructure, or drop. 3. Name the document buy-side QoE lead still needs before signing. 4. For this M&A Due Diligence People and Contracts file, read regulatory-approval critical-path calendar against a founder who will not sign a non-compete and write the one fact that would move to re-trade, restructure, or drop for buy-side QoE lead.

RECOMMENDATION Choose To re-trade, restructure, / Drop on this M&A Due Diligence / People and Contracts packet (regulatory-approval critical-path calendar after a founder who will not sign a non-compete). The follow-on People and Contracts action is what buy-side QoE lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line M&A Due Diligence option on to re-trade, restructure, or drop, then the evidence in regulatory-approval critical-path calendar, then the action for buy-side QoE lead - Hypothesis scorecard against regulatory-approval critical-path calendar: supported / rejected / untestable - Missing page in regulatory-approval critical-path calendar after a founder who will not sign a non-compete, if any - Regulatory or exam hook People and Contracts would cite